• Redundancy of all employee positions, including CEO and MD
• Significant reduction in other expenditures while preserving intellectual property
• Secured a $600,000 R&D TI Loan against 2026 financial year R&D rebate

Cynata Therapeutics Limited has announced substantial changes in its management structure, including the redundancy of all employee positions, such as the CEO and Managing Director. The company has also significantly reduced other expenditures while ensuring the preservation of its intellectual property. Additionally, Cynata has secured a Research and Development Tax Incentive (R&D TI) loan of $600,000, which is secured against the anticipated R&D TI rebate for the 2026 financial year. The company's cash runway has been extended beyond the end of the 2027 financial year, providing stability as the Board evaluates next steps for the company's development.

Cynata expects a cash burn of approximately $2.3m for the entire 2027 financial year.

The Board is evaluating options for the further development of the Cymerus technology and will update shareholders on these matters soon.